Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRONTO-Peds: ultra-rapid lispro versus Humalog in pediatric type 1 diabetes
MOH_2019-03-27_006053Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of human insulin and insulin lispro in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to week 26. Started Jan 2019; status: completed.
02
Drugs
human insulininsulin lispro
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on MOH_2019-03-27_006053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-27_006053.